Abstract
Twenty-eight patients with advanced or recurrent adenocarcinoma of the endometrium were treated with m-AMSA. Twenty-four patients (86%) were treated at 30 mg/M2/d × 3d q 21 d and four patients were treated at 40 mg/M2/d × 3d q 21 d intravenously. Eighty-eight courses of m-AMSA were administered with a median of 2 courses per patient. One (5%) complete response occurred in 19 patients evaluable for response. Toxicity was well tolerated and generally mild. m-AMSA may be relatively inactive in the treatment of advanced adenocarcinoma of the endometrium; further studies, however, are required to determine its effectiveness in primary previously untreated disease.
Original language | English (US) |
---|---|
Pages (from-to) | 335-338 |
Number of pages | 4 |
Journal | Investigational New Drugs |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1984 |
Keywords
- 4′-(9-acridinyl-amino)methanesulfon-m-anisidide
- Phase II clinical trial
- adenocarcinoma of the endometrium
- m-AMSA
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)